Gsk (GLAXF) Receivables Refunds (2016 - 2025)
Gsk has reported Receivables Refunds over the past 10 years, most recently at $383.1 million for Q4 2025.
- Quarterly results put Receivables Refunds at $383.1 million for Q4 2025, down 38.96% from a year ago — trailing twelve months through Dec 2025 was $383.1 million (down 38.96% YoY), and the annual figure for FY2025 was $383.1 million, down 38.96%.
- Receivables Refunds for Q4 2025 was $383.1 million at Gsk, down from $627.6 million in the prior quarter.
- Over the last five years, Receivables Refunds for GLAXF hit a ceiling of $655.1 million in Q4 2021 and a floor of $383.1 million in Q4 2025.
- Median Receivables Refunds over the past 5 years was $475.0 million (2022), compared with a mean of $520.8 million.
- Biggest five-year swings in Receivables Refunds: skyrocketed 35.57% in 2024 and later crashed 38.96% in 2025.
- Gsk's Receivables Refunds stood at $655.1 million in 2021, then fell by 27.49% to $475.0 million in 2022, then decreased by 2.54% to $462.9 million in 2023, then soared by 35.57% to $627.6 million in 2024, then tumbled by 38.96% to $383.1 million in 2025.
- The last three reported values for Receivables Refunds were $383.1 million (Q4 2025), $627.6 million (Q4 2024), and $462.9 million (Q4 2023) per Business Quant data.